Table 4.
Treatment outcome by FCGR2A genotype, KRAS or BRAF mutational status, and therapy received
|
FLOX |
FLOX + cetuximab |
|
|||||
|---|---|---|---|---|---|---|---|
| H/H | H/R | R/R | H/H | H/R | R/R | Interaction P -value | |
|
KRAS
wild-type (N = 273) | |||||||
| Number of patients |
N = 16 |
N = 52 |
N = 20 |
N = 46 |
N = 98 |
N = 41 |
|
| Response |
63% (10/16) |
42% (22/52) |
45% (9/20) |
46% (21/46) |
51% (50/98) |
56% (23/41) |
0.27* |
| PFS |
8.4 |
8.9 |
9.0 |
7.7 |
7.7 |
8.0 |
0.23† |
| OS |
31.6 |
23.6 |
19.0 |
21.4 |
20.7 |
18.9 |
0.23† |
|
KRAS
mutated (N = 169) | |||||||
| Number of patients |
N = 10 |
N = 25 |
N = 21 |
N = 28 |
N = 57 |
N = 28 |
|
| Response |
60% (6/10) |
52% (13/25) |
19% (4/21) |
36% (10/28) |
46% (26/57) |
50% (14/28) |
0.04* |
| PFS |
8.1 |
8.3 |
7.1 |
7.7 |
8.1 |
6.7 |
0.90† |
| OS |
17.2 |
20.4 |
24.3 |
21.1 |
20.0 |
16.8 |
0.34† |
|
BRAF
wild-type (N = 363) | |||||||
| Number of patients |
N = 22 |
N = 62 |
N = 34 |
N = 58 |
N = 130 |
N = 57 |
|
| Response |
64% (14/22) |
48% (30/62) |
35% (12/34) |
47% (27/58) |
52% (68/130) |
54% (31/57) |
0.10* |
| PFS |
9.3 |
8.9 |
7.7 |
8.5 |
8.1 |
8.0 |
0.47† |
| OS |
31.6 |
23.8 |
21.5 |
21.9 |
21.5 |
17.6 |
0.93† |
|
BRAF
mutated (N = 47) | |||||||
| Number of patients |
N =3 |
N = 10 |
N = 4 |
N = 8 |
N = 16 |
N = 6 |
|
| Response |
33% (1/3) |
20% (2/10) |
0% (0/4) |
13% (1/8) |
25% (4/16) |
33% (2/6) |
0.72* |
| PFS |
4.3 |
5.1 |
3.8 |
3.8 |
4.6 |
5.8 |
0.36† |
| OS | 9.2 | 9.4 | 5.6 | 8.9 | 8.1 | 11.3 | 0.73† |
*Logistic regression, †Cox proportional hazard model.